Oasmia expands the Management Team

Udgivet den 10-04-2019  |  kl. 06:00  |  

Oasmia Pharmaceutical AB (NASDAQ: OASM) expands the Management Team in order to directly involve the whole organization in the commercialization of Apealea and other product candidates.

Earlier the Management Team was formed only by the CEO, the CFO and the Executive Chairman.

The following persons are now part of the Management Team.

Mikael Asp, CEO
Anette Sjödin, Chief Business Officer (CBO) and deputy CEO
Joakim Lindén, acting CFO
Sven Rohmann, acting Chief Medical Officer (CMO) (also Member of the Board)
Nina Heldring, Head of Clinical Development
Maria Nilsson Hagberg, Head of Regulatory Affairs
Dzianis Babrou, Head of Research and Development
Elin Trampe, Head of Supply Chain
Richard Herrmann, Strategic Marketing Director

"With this Management Team, Oasmia gets direct access to all necessary competences enabling a successful commercialization of its products. Furthermore, this set up ensures a qualified, fast and transparent decision making as well as immediate implementation since more department heads now are parts of the process", says Mikael Asp, CEO of Oasmia.

For more information:
Mikael Asp, CEO
Tel: +46 18 50 54 40
E-mail: mikael.asp@oasmia.com

For further information, email: IR@oasmia.com

Note to editors:

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

This information was submitted for publication, through the agency of the contact person set out above, at 08:00 PM CET on 10 April 2019.

Attachment

PR Management EN 190410

\Hugin

Udgivet af: NPinvestordk

Mest læste lige nu

Aktier/tendens: Afhængig af fortsatte udsving i Novo og Vestas ordreudvikling
Vestas løber med australsk ordre
Novos Victoza får første generiske konkurrent godkendt i USA
Novos styrtdyk sidste fredag var en overreaktion mener amerikansk storbank
ECB's Lagarde: Meget tæt på at nå inflationsmål
 

Seneste nyheder

10:30 Ennogie får bekræftet sidste del tysk ordre på 2-5 mio. kr.
10:25 Obligationer/åbning: Renteløft i USA trækker danske rente med op
10:07 GN kæmper fortsat mod spekulanter: Usikkerhed om Enterprise og toldsatser lægger pres på
09:33 Aktier/åbning: Fortsat revanche til Novo i toppen af positivt indeks
08:50 Novos styrtdyk sidste fredag var en overreaktion mener amerikansk storbank
08:45 Jeudan reducerer renterisikoen: Vil måles på kernedriften
08:41 NKT tildelt to højspændingsprojekter under eksisterende rammeaftale
08:34 Råvarer: Oliepriserne er klar på ugentlig gevinst efter optimisme om kinesiske stimulanser
08:26 Vigtigt rateindeks for Mærsk stiger for femte uge i træk
08:25 Aktier/tendens: Afhængig af fortsatte udsving i Novo og Vestas ordreudvikling
07:18 Obligationer/tendens: Måske et svagt rentefald i tyndt marked efter fald i USA
07:04 Asien: I plus for femte handelsdag i streg
06:56 Mærsks asiatiske konkurrenter har uensartet udvikling fredag
06:35 Novos Victoza får første generiske konkurrent godkendt i USA
06:35 ECB's Lagarde: Meget tæt på at nå inflationsmål
06:34 Vestas løber med australsk ordre
06:33 Asien: I plus for femte handelsdag i streg
06:33 Valuta: Dollar i stærkeste niveau over for yen i fem måneder
06:32 USA/T-bond: Renter tikkede op mandag - faldt lidt tilbage i juledagene
06:32 USA/lukning: Chipaktier hev markedet op mandag før jul